Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, twice-yearly exenatide subdermal implant under development for ...

Feb 28 (Reuters) - Vivani Medical VANI.O shares surged more than five-fold in early trading on Wednesday after the drug developer said its experimental under-the-skin drug implant helped reduce weight ...

Vivani Medical began the LIBERATE-1 trial, testing a six-month exenatide implant for chronic weight management in Australia. The study uses NanoPortal technology, with results expected in mid-2025 and ...